Question

The recently FDA-approved intravenous fat emulsion (IVFE), known as Smoflipid, differs from soybean oil-based fat emulsion in that it

1: contains egg yolk phospholipid as an emulsifying agent.
2: may be infused via peripheral or central intravenous line.
3: also contains MCT oil, olive oil and fish oil.
4: provides essential fatty acids (EFAs).

Answer 1

Smoflipid is a multi-oil intravenous fat emulsion containing soybean oil, MCT oil, olive oil, and fish oil, which provides essential fatty acids. It uses egg yolk phospholipids for emulsifying and can be infused via different intravenous routes.

Step-by-step explanation:

Smoflipid, an FDA-approved intravenous fat emulsion, differs from traditional soybean oil-based fat emulsions by incorporating multiple oil sources. Unlike soybean-only emulsions, Smoflipid includes a blend of soybean oil, medium-chain triglycerides (MCT) oil, olive oil, and fish oil. This mixture provides a more balanced fatty acid profile, including essential fatty acids (EFAs). It is formulated to enhance the safety and efficacy of parenteral nutrition. Moreover, the emulsifying agent in Smoflipid is egg yolk phospholipid, which, similar to lecithin found in bile, helps with the stable dispersal of these oils in an aqueous solution. This emulsification is critical for the digestion and absorption of lipids, as it enables the fats to be suspended in the watery environment of the bloodstream. Smoflipid can be administered through both peripheral and central intravenous lines, offering flexible infusion options.